Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JKBCS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
B7H3-EC3 DAR7.8
|
|||||
| Synonyms |
B7H3 EC3; B7H3EC3
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute granulocytic leukaemia [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-human CD276 mAb
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
NAMPT inhibitor 4
|
Payload Info | ||||
| Therapeutic Target |
Nicotinamide phosphoribosyltransferase (NAMPT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Maleimide was used for Michael addition reactions with the thiol groups of the antibody that were generated through the reduction of interchain disulfide bonds.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.50% (Day 30) | High CD276 expression (CD276+++) | ||
| Method Description |
The in vivo antitumor efficacy and tolerability of the selected NAMPTi-ADCs were evaluated in the cell line-derived THP-1 human AmL xenograft model.Treatment with the high-DAR B7H3-EC3 (DAR 7.8; 5 mg/kg,iv,Q7Dx3).
|
||||
| In Vivo Model | Monocytic leukemia CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.